lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-19. Numbers and descriptions here follow the published literature rather than marketing material.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
As there are a number of different electron donors (organic matter in organotrophs, inorganic matter in lithotrophs), there are a number of different electron acceptors, both organic and inorganic. As with other steps of the ETC, an enzyme is required to help with the process. If oxygen is available, it is most often used as the terminal electron acceptor in aerobic bacteria and facultative anaerobes. An oxidase reduces the O2 to water while oxidizing something else. In mitochondria, the terminal membrane complex (Complex IV) is cytochrome oxidase, which oxidizes the cytochrome. Aerobic bacteria use a number of different terminal oxidases. For example, E. coli (a facultative anaerobe) does not have a cytochrome oxidase or a bc1 complex. Under aerobic conditions, it uses two different terminal quinol oxidases (both proton pumps) to reduce oxygen to water. Bacterial terminal oxidases can be split into classes according to the molecules act as terminal electron acceptors. Class I oxidases are cytochrome oxidases and use oxygen as the terminal electron acceptor. Class II oxidases are quinol oxidases and can use a variety of terminal electron acceptors. Both of these classes can be subdivided into categories based on what redox-active components they contain. E.g. Heme aa3 Class 1 terminal oxidases are much more efficient than Class 2 terminal oxidases. Mostly in anaerobic environments different electron acceptors are used, including nitrate, nitrite, ferric iron, sulfate, carbon dioxide, and small organic molecules such as fumarate.
=== Structural domains === All of the isoforms of CaMKII have: a catalytic domain, an autoinhibitory regulatory domain, a variable segment, and a self-association domain. The catalytic domain binds ATP and substrate proteins; it is responsible for the transfer of phosphate from ATP to Ser or Thr residues in the substrate proteins. The autoinhibitory regulatory domain features a pseudosubstrate site, which binds to the catalytic domain and blocks its ability to phosphorylate proteins. The structural feature that governs this autoinhibition is the Threonine 286 residue. Phosphorylation of this site will permanently activate the CaMKII enzyme. Once the Threonine 286 residue has been phosphorylated, the inhibitory domain is blocked from the pseudosubstrate site. This effectively blocks autoinhibition, allowing for permanent activation of the CaMKII enzyme. This enables CaMKII to be active, even in the absence of calcium and calmodulin. The other two domains in CaMKII are the variable and self-association domains. Differences in these domains contribute to the various CaMKII isoforms. The self-association domain (CaMKII AD) is found at the C terminus, the function of this domain is the assembly of the single proteins into large (8 to 14 subunits) multimers.
At the age of 14, Zverev entered qualifying at three different tournaments, including the 2011 Moselle Open on the ATP Tour, but lost all of his matches. He won his professional main draw debut against compatriot Christian Lichtenegger at a Futures event in Germany in August 2012. At the end of the year, he made his first professional final, finishing runner-up to Florian Reynet at an ITF $10K event in Florida. Zverev continued to focus on the juniors in 2013 and did not reach another pro-level final that year, but he did make his main draw debut on the ATP Tour in July, losing to Roberto Bautista Agut at his hometown tournament, the International German Open. He also made his ATP Challenger Tour debut, losing to Máximo González at the Meerbusch Challenger in August. After winning the boys' singles title at the 2014 Australian Open, Zverev shifted his focus to his professional career, only playing in pro events the rest of the year. Initially, he struggled on the pro tour, failing to qualify for the main draw at his first five events of the season. He did not win a main draw match until he recorded a single victory at the Heilbronner Neckarcup Challenger, his tenth event of the year. One of his losses was a retirement against his brother Mischa. Zverev made his first professional breakthrough in July when he won the Braunschweig Challenger for his first professional title, despite entering the tournament with just one career Challenger-level match win and no top 100 victories. Three of the players he defeated were in the top 100, including his first-round opponent No.
Sources: en.wikipedia.org
== Regulation of expression and activity == The formation of guanidinoacetate is normally the rate-limiting step of creatine biosynthesis. Consequently, the AGAT reaction is the most likely control step in the pathway, a hypothesis that is supported by a great deal of experimental work. Most important in this respect is the feedback repression of AGAT by creatine, the end-product of the pathway. Cyclocreatine, N-acetimidoylsarcosine, and N-ethylguanidinoacetate display repressor activity like creatine as well. L-Arginine and guanidinoacetate have only "apparent" repressor activity. They exert no effect on AGAT expression by themselves but are readily converted to creatine, which then acts as the true repressor. It has been suggested that AGAT activity in tissues is regulated in a number of ways including induction by growth hormone and thyroxine, inhibition of the enzyme by ornithine, and repression of its synthesis by creatine. Sex hormones may regulate the activity of AGAT. Treatment of male rats with testosterone propionate increases AGAT activity. In contrast, estrogen treatment decreases AGAT activity and induces weight loss. It is currently unclear whether the changes in the level of AGAT transcript results from altered mRNA stability or enhanced transcriptional rate. If estrogen-mediated alteration results from transcriptional regulation, the site of estrogen action is yet to be determined. GATM expression within the mouse placenta has been shown to be imprinted meaning only the maternal copy of GATM is expressed .
Exactly one month after the declaration was issued, a large-scale celebration took place at the Royal Opera House – speeches were given by leading Zionists as well as members of the British administration including Sykes and Cecil. From 1918 until the Second World War, Jews in Mandatory Palestine celebrated Balfour Day as an annual national holiday on 2 November. The celebrations included ceremonies in schools and other public institutions and festive articles in the Hebrew press. In August 1919 Balfour approved Weizmann's request to name the first post-war settlement in Mandatory Palestine, "Balfouria", in his honour. It was intended to be a model settlement for future American Jewish activity in Palestine. Herbert Samuel, the Zionist MP whose 1915 memorandum had framed the start of discussions in the British Cabinet, was asked by Lloyd George on 24 April 1920 to act as the first civil governor of British Palestine, replacing the previous military administration that had ruled the area since the war. This decision reflected a clear pro-Zionist stance by the British government. Shortly after beginning the role in July 1920, he was invited to read the haftarah from Isaiah 40 at the Hurva Synagogue in Jerusalem, which, according to his memoirs, led the congregation of older settlers to feel that the "fulfilment of ancient prophecy might at last be at hand".
In the 19th century, it was common to give children a mixture of sulfur and treacle as a remedy. The sulfur in it was meant to act as a spring tonic and a laxative. Reportedly foul-tasting, "brimstone and treacle" was considered by many an unpleasant childhood experience, and it is mentioned as such in a number of cultural references, including Mary Poppins, the works of Charles Dickens, and the controversial 1976 British play of the same name. Madam C. J. Walker, who became the first female millionnaire by selling hair products for Black women in the early 1900s, notably used sulfur as an ingredient in her products. Sulfur was also used in fumigations against the plague. In the early 20th century, during the Third Plague Pandemic, devices like the Clayton machine, used in harbors across the world, or the Sulfurozador in Latin America, were used to spread sulfur dioxide gas to kill insects, rats and pathogens.
Sources: en.wikipedia.org
All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for opioid use disorder in their practice if permitted by applicable state law. The Substance Abuse and Mental Health Services Administration encourages practitioners to treat patients within their practices who require treatment for a substance use disorder. Because it may now be prescribed much more readily out of an office setting (as opposed to methadone, which requires specialized centers), buprenorphine/naloxone allows people more access to this medication and more freedom of administration. It also thus comes with more risks in this vulnerable population. Buprenorphine/naloxone may be recommended for socially stable people who use opioids who cannot retrieve medications from a center daily, who have another condition requiring regular primary care visits, or who have jobs or daily lives that require they maintain all their faculties and cannot take a sedating medication. Buprenorphine/naloxone is also recommended over methadone for people at high risk of methadone toxicity, such as the elderly, those taking high doses of benzodiazepines or other sedating substances, concomitant alcohol use disorder, those with a lower level of opioid tolerance, and those at high risk of prolonged QT interval. It is also helpful to use the medication in combination with psychosocial support and counseling.
The FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent. It is the first approval for head and neck squamous cell carcinoma in six years and the first overall perioperative approval for locally advanced head and neck squamous cell carcinoma. In November 2025, the US FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa with enfortumab vedotin as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer who are ineligible for cisplatin.
==== Molecular and signaling response to LTP-inducing stimuli ==== The mechanism for LTP has long been a topic of debate, but, recently, mechanisms have come to some consensus. AMPARs play a key role in this process, as one of the key indicators of LTP induction is the increase in the ratio of AMPAR to NMDARs following high-frequency stimulation. The idea is that AMPARs are trafficked from the dendrite into the synapse and incorporated through some series of signaling cascades. AMPARs are initially regulated at the transcriptional level at their 5' promoter regions. There is significant evidence pointing towards the transcriptional control of AMPA receptors in longer-term memory through cAMP response element-binding protein (CREB) and mitogen-activated protein kinases (MAPK). Messages are translated on the rough endoplasmic reticulum (rough ER) and modified there. Subunit compositions are determined at the time of modification at the rough ER. After post-ER processing in the Golgi apparatus, AMPARs are released into the perisynaptic membrane as a reserve waiting for the LTP process to be initiated. The first key step in the process following glutamate binding to NMDARs is the influx of calcium through the NMDA receptors and the resultant activation of Ca2+/calmodulin-dependent protein kinase (CaMKII). Blocking either this influx or the activation of CaMKII prevents LTP, showing that these are necessary mechanisms for LTP. In addition, profusion of CaMKII into a synapse causes LTP, showing that it is a causal and sufficient mechanism.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.